Sébastien Lemieux
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sébastien Lemieux has a total of 399 co-authors. Here are the top co-authors by number of shared publications:
- Claude Perreault
Université de Montréal
30 shared publications - Patrick Gendron
Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada
27 shared publications - Pierre Thibault
University of Montreal
24 shared publications - Guy Sauvageau
Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Canada
23 shared publications - Jean-Philippe Laverdure
Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC H3T 1J4, Canada
19 shared publications - Mathieu Courcelles
IRIC, Université de Montréal
19 shared publications
Latest Publications
- Open Access
PHATE-Derived Ancestry Coordinates Capture Continuous Population Structure in Human Genomic Data
Population genetic data are increasingly visualized using low-dimensional embeddings as ancestry coordinates, yet how these methods represent population structure can depend strongly on sampling and construction choices. Principal component analysis (PCA), when visualized using only leading components, can obscure fine-scale structure, while nonlinear neighbor-based methods such as uniform manifold approximation and projection (UMAP) often fragment geographic and admixture gradients into discrete clusters. Here, we introduce a framework for constructing ancestry coordinates using potential of heat-diffusion for affinity-based trajectory embedding (PHATE), a diffusion-based method that preserves relationships across scales. Across synthetic benchmarks and large genomic datasets, we show that appropriate scale tuning and population balancing allow PHATE to recover geographic organization and admixture gradients. We show that incorrectly tuned neighborhood scale and population imbalance can distort the resulting representations of population structure. These results therefore provide a methodological framework and practical guidance for constructing ancestry visualizations that better reflect continuous human genetic diversity.
Open AccessPHATE-Derived Ancestry Coordinates Capture Continuous Population Structure in Human Genomic Data
Population genetic data are increasingly visualized using low-dimensional embeddings as ancestry coordinates, yet how these methods represent population structure can depend strongly on sampling and construction choices. Principal component analysis (PCA), when visualized using only leading components, can obscure fine-scale structure, while nonlinear neighbor-based methods such as uniform manifold approximation and projection (UMAP) often fragment geographic and admixture gradients into discrete clusters. Here, we introduce a framework for constructing ancestry coordinates using potential of heat-diffusion for affinity-based trajectory embedding (PHATE), a diffusion-based method that preserves relationships across scales. Across synthetic benchmarks and large genomic datasets, we show that appropriate scale tuning and population balancing allow PHATE to recover geographic organization and admixture gradients. We show that incorrectly tuned neighborhood scale and population imbalance can distort the resulting representations of population structure. These results therefore provide a methodological framework and practical guidance for constructing ancestry visualizations that better reflect continuous human genetic diversity.
- 28 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF17
EZH2 Inhibition Induces a Metabolic Stress Response, Sensitizing Triple-Negative Breast Cancer to Glutaminase Targeting
Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the histone methyltransferase complex polycomb repressive complex 2, is overexpressed and associated with a poor prognosis in triple-negative breast cancer (TNBC). Although EZH2 inhibition significantly alters chromatin landscapes and gene expression, it has a limited impact on the growth of TNBC models, suggesting adaptive compensatory mechanisms. In this study, we demonstrated that EZH2 inhibition causes the accumulation of misfolded proteins and double-stranded RNA, triggering an essential integrated stress response (ISR) through protein kinase R and protein kinase RNA–like endoplasmic reticulum kinase activation. By inducing ISR-mediated activating transcription factor 4 (ATF4), EZH2 inhibition enhanced amino acid flux and promoted glutaminolysis to support TNBC cell survival. Pharmacologic targeting of this metabolic axis with a glutaminase inhibitor in combination with EZH2 inhibition significantly impaired TNBC cell proliferation and tumor growth. These findings reveal a stress-driven metabolic adaptation that sustains TNBC survival upon EZH2 blockade and highlight the inhibition of this pathway as a strategy to enhance the efficacy of EZH2 inhibitors in TNBC. Significance: By inducing integrated stress response–ATF4-mediated metabolic rewiring, EZH2 inhibition creates a critical glutamine dependency in triple-negative breast cancer, exposing an actionable vulnerability through co-inhibition of glutaminase.
- 28 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF17
EZH2 Inhibition Induces a Metabolic Stress Response, Sensitizing Triple-Negative Breast Cancer to Glutaminase Targeting
Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the histone methyltransferase complex polycomb repressive complex 2, is overexpressed and associated with a poor prognosis in triple-negative breast cancer (TNBC). Although EZH2 inhibition significantly alters chromatin landscapes and gene expression, it has a limited impact on the growth of TNBC models, suggesting adaptive compensatory mechanisms. In this study, we demonstrated that EZH2 inhibition causes the accumulation of misfolded proteins and double-stranded RNA, triggering an essential integrated stress response (ISR) through protein kinase R and protein kinase RNA–like endoplasmic reticulum kinase activation. By inducing ISR-mediated activating transcription factor 4 (ATF4), EZH2 inhibition enhanced amino acid flux and promoted glutaminolysis to support TNBC cell survival. Pharmacologic targeting of this metabolic axis with a glutaminase inhibitor in combination with EZH2 inhibition significantly impaired TNBC cell proliferation and tumor growth. These findings reveal a stress-driven metabolic adaptation that sustains TNBC survival upon EZH2 blockade and highlight the inhibition of this pathway as a strategy to enhance the efficacy of EZH2 inhibitors in TNBC. Significance: By inducing integrated stress response–ATF4-mediated metabolic rewiring, EZH2 inhibition creates a critical glutamine dependency in triple-negative breast cancer, exposing an actionable vulnerability through co-inhibition of glutaminase.
- Open Access
A biological-response compound representation allows chemical perturbation prediction across cell lines
Accurately predicting cellular responses to drugs remains a challenge with the potential to reduce experimental screening costs and accelerate drug discovery. Current computational approaches represent compounds through chemical structures, which carry little information regarding their activity within biological systems. We show that gene expression responses, measured in a reference cell line, can instead serve as transferable representations of chemical perturbations. The proposed framework, BioPert, uses biological representations with a small neural network to predict transcriptional delta responses in cell lines of different lineages. Across the Tahoe-100M and LINCS L1000 datasets, BioPert outperforms molecular fingerprints and embeddings learned from chemical structure, which provide limited improvements over random controls. BioPert’s prediction correlations reach 0.79 on Tahoe-100M, corresponding to an improvement of 0.34 over the next-best representation. On LINCS, performance varies with the experimental reproducibility of the test conditions, highlighting the impact of batch effects. Notably, BioPert considerably surpasses predictions obtained by copying the reference response, demonstrating that it captures context-dependent effects. Further analysis of a C32-cobimetinib case shows pathway-level accuracy of the predictions, including when the reference and target responses differ. These results open a new path for chemical perturbation prediction and could ultimately reduce the burden of phenotypic screening.
Open AccessA biological-response compound representation allows chemical perturbation prediction across cell lines
Accurately predicting cellular responses to drugs remains a challenge with the potential to reduce experimental screening costs and accelerate drug discovery. Current computational approaches represent compounds through chemical structures, which carry little information regarding their activity within biological systems. We show that gene expression responses, measured in a reference cell line, can instead serve as transferable representations of chemical perturbations. The proposed framework, BioPert, uses biological representations with a small neural network to predict transcriptional delta responses in cell lines of different lineages. Across the Tahoe-100M and LINCS L1000 datasets, BioPert outperforms molecular fingerprints and embeddings learned from chemical structure, which provide limited improvements over random controls. BioPert’s prediction correlations reach 0.79 on Tahoe-100M, corresponding to an improvement of 0.34 over the next-best representation. On LINCS, performance varies with the experimental reproducibility of the test conditions, highlighting the impact of batch effects. Notably, BioPert considerably surpasses predictions obtained by copying the reference response, demonstrating that it captures context-dependent effects. Further analysis of a C32-cobimetinib case shows pathway-level accuracy of the predictions, including when the reference and target responses differ. These results open a new path for chemical perturbation prediction and could ultimately reduce the burden of phenotypic screening.
- Open Access
STING dampens the unfolded protein response to enable the presentation of self-antigens on MHC-I during inflammation
Summary: A growing body of evidence supports the contribution of the long-lasting adaptive immune system in Parkinson’s disease (PD). We showed that the PD-associated protein PINK1 negatively regulates the presentation of mitochondrial antigens (MitAP) on MHC-I molecules. In vivo evidence indicated that MitAP activation in mice, in the absence of PINK1, led to cytotoxic CD8 + T cell stimulation and severe motor impairments, reversible by L-DOPA. We show here that following TLR4 activation, MitAP is engaged through a pathway involving cGAS-STING, which acts as a rheostat to dampen the unfolded protein response (UPR). Without STING, the stress response is amplified, leading to a translational attenuation that inhibits the expression of XBP1s, a transcription factor required for MitAP. STING activity also regulates the repertoire of peptides displayed at the cell surface during inflammation, highlighting a potential role in immunosurveillance. These findings establish STING and the UPR as key immune regulators targetable for therapeutic intervention during autoimmune diseases and PD.
Open AccessSTING dampens the unfolded protein response to enable the presentation of self-antigens on MHC-I during inflammation
Summary: A growing body of evidence supports the contribution of the long-lasting adaptive immune system in Parkinson’s disease (PD). We showed that the PD-associated protein PINK1 negatively regulates the presentation of mitochondrial antigens (MitAP) on MHC-I molecules. In vivo evidence indicated that MitAP activation in mice, in the absence of PINK1, led to cytotoxic CD8 + T cell stimulation and severe motor impairments, reversible by L-DOPA. We show here that following TLR4 activation, MitAP is engaged through a pathway involving cGAS-STING, which acts as a rheostat to dampen the unfolded protein response (UPR). Without STING, the stress response is amplified, leading to a translational attenuation that inhibits the expression of XBP1s, a transcription factor required for MitAP. STING activity also regulates the repertoire of peptides displayed at the cell surface during inflammation, highlighting a potential role in immunosurveillance. These findings establish STING and the UPR as key immune regulators targetable for therapeutic intervention during autoimmune diseases and PD.
- Open Access
- 7 January 2026
- Published by Oxford University Press (OUP) in Bioinformatics Advances
- Vol. 6 (1)
BiDRA: Bayesian inference as a robust alternative to non-linear regression for dose–response efficiency metrics assessment
Motivation: Dose–response metrics such as the half-maximal inhibitory concentration, high-dose–response, and slope are central to drug discovery, yet standard Levenberg–Marquardt fits often produce biased or unsupported values for incomplete curves and lack uncertainty measures. In practice, this forces experimenters to visually inspect each curve fit to judge its reliability, a tedious, subjective, and non-scalable process. Results: Across 421 405 public dose–response experiments from three large pharmacogenomic datasets, shared-concentration viability responses were highly consistent across biological replicates, making it reasonable to expect derived efficiency metrics to show comparable replicate behavior when supported by the data. However, Levenberg–Marquardt fits to incomplete curves often produced unsupported metric values, including inflated rates of observable potency estimates (>70% versus ∼39% complete curves), which could falsely suggest metric-level disagreement between similar replicate responses. BiDRA represents efficacy, potency, and slope as posterior distributions, allowing uncertainty to remain large when the data do not support precise metric inference. This avoids treating uncertainty-dominated responses as conflicting point estimates, exposes unsupported Levenberg–Marquardt estimates, and supports uncertainty-aware compound ranking. We illustrate its utility in a structure–activity relationship screen, demonstrating how posteriors enable robust, criteria-based selection in drug discovery settings. Availability and implementation: BiDRA is implemented in Julia and available at https://github.com/lemieux-lab/bidra_robustness.
- 7 January 2026
- Published by Oxford University Press (OUP) in Bioinformatics Advances
- Vol. 6 (1)
Open AccessBiDRA: Bayesian inference as a robust alternative to non-linear regression for dose–response efficiency metrics assessment
Motivation: Dose–response metrics such as the half-maximal inhibitory concentration, high-dose–response, and slope are central to drug discovery, yet standard Levenberg–Marquardt fits often produce biased or unsupported values for incomplete curves and lack uncertainty measures. In practice, this forces experimenters to visually inspect each curve fit to judge its reliability, a tedious, subjective, and non-scalable process. Results: Across 421 405 public dose–response experiments from three large pharmacogenomic datasets, shared-concentration viability responses were highly consistent across biological replicates, making it reasonable to expect derived efficiency metrics to show comparable replicate behavior when supported by the data. However, Levenberg–Marquardt fits to incomplete curves often produced unsupported metric values, including inflated rates of observable potency estimates (>70% versus ∼39% complete curves), which could falsely suggest metric-level disagreement between similar replicate responses. BiDRA represents efficacy, potency, and slope as posterior distributions, allowing uncertainty to remain large when the data do not support precise metric inference. This avoids treating uncertainty-dominated responses as conflicting point estimates, exposes unsupported Levenberg–Marquardt estimates, and supports uncertainty-aware compound ranking. We illustrate its utility in a structure–activity relationship screen, demonstrating how posteriors enable robust, criteria-based selection in drug discovery settings. Availability and implementation: BiDRA is implemented in Julia and available at https://github.com/lemieux-lab/bidra_robustness.
- Open Access
EZH2 Inhibition Induces a Metabolic Stress Response Sensitizing TNBC to Glutaminase Targeting
EZH2, the catalytic subunit of Polycomb Repressive Complex II, is overexpressed and associated with poor prognosis in triple-negative breast cancer (TNBC). Although EZH2 inhibition induces significant changes in chromatin landscapes and gene expression, it has a limited impact on the growth of TNBC models, suggesting adaptive compensatory mechanisms. Here, we demonstrate that EZH2 inhibition leads to the accumulation of misfolded proteins and double-stranded RNA (dsRNA), triggering an essential integrated stress response (ISR) through PKR and PERK activation. By inducing ISR-mediated ATF4 activation, EZH2 inhibition enhances amino acid flux and promotes glutaminolysis, in turn activating mTOR signaling to support TNBC cell survival. Pharmacological targeting of this metabolic adaptation with a glutaminase (GLS) inhibitor in combination with EZH2 inhibition significantly impairs TNBC cell proliferation and tumor growth. These findings reveal a stress-driven metabolic adaptation that sustains TNBC survival upon EZH2 blockade and highlight inhibition of this pathway as a strategy to enhance the efficacy of EZH2 inhibitors in TNBC.
Open AccessEZH2 Inhibition Induces a Metabolic Stress Response Sensitizing TNBC to Glutaminase Targeting
EZH2, the catalytic subunit of Polycomb Repressive Complex II, is overexpressed and associated with poor prognosis in triple-negative breast cancer (TNBC). Although EZH2 inhibition induces significant changes in chromatin landscapes and gene expression, it has a limited impact on the growth of TNBC models, suggesting adaptive compensatory mechanisms. Here, we demonstrate that EZH2 inhibition leads to the accumulation of misfolded proteins and double-stranded RNA (dsRNA), triggering an essential integrated stress response (ISR) through PKR and PERK activation. By inducing ISR-mediated ATF4 activation, EZH2 inhibition enhances amino acid flux and promotes glutaminolysis, in turn activating mTOR signaling to support TNBC cell survival. Pharmacological targeting of this metabolic adaptation with a glutaminase (GLS) inhibitor in combination with EZH2 inhibition significantly impairs TNBC cell proliferation and tumor growth. These findings reveal a stress-driven metabolic adaptation that sustains TNBC survival upon EZH2 blockade and highlight inhibition of this pathway as a strategy to enhance the efficacy of EZH2 inhibitors in TNBC.
- Open Access
A Transparent and Generalizable Deep Learning Framework for Genomic Ancestry Prediction
1 Accurately capturing genetic ancestry is critical for ensuring reproducibility and fairness in genomic studies and downstream health research. This study aims to address the prediction of ancestry from genetic data using deep learning, with a focus on generalizability across datasets with diverse populations and on explainability to improve model transparency. We adapt the Diet Network, a deep learning architecture proven effective in handling high-dimensional data, to learn population ancestry from single nucleotide polymorphisms (SNPs) data using the populational Thousand Genomes Project dataset. Our results highlight the model’s ability to generalize to diverse populations in the CARTaGENE and Montreal Heart Institute biobanks and that predictions remain robust to high levels of missing SNPs. We show that, despite the lack of North African populations in the training dataset, the model learns latent representations that reflect meaningful population structure for North African individuals in the biobanks. To improve model transparency, we apply Saliency Maps, DeepLift, GradientShap and Integrated Gradients attribution techniques and evaluate their performance in identifying SNPs leveraged by the model. Using DeepLift, we show that model’s predictions are driven by population-specific signals consistent with those identified by traditional population genetics metrics. This work presents a generalizable and interpretable deep learning framework for genetic ancestry inference in large-scale biobanks with genetic data. By enabling more widespread genomic ancestry characterization in these cohorts, this study contributes practical tools for integrating genetic data into downstream biomedical applications, supporting more inclusive and equitable healthcare solutions.
Open AccessA Transparent and Generalizable Deep Learning Framework for Genomic Ancestry Prediction
1 Accurately capturing genetic ancestry is critical for ensuring reproducibility and fairness in genomic studies and downstream health research. This study aims to address the prediction of ancestry from genetic data using deep learning, with a focus on generalizability across datasets with diverse populations and on explainability to improve model transparency. We adapt the Diet Network, a deep learning architecture proven effective in handling high-dimensional data, to learn population ancestry from single nucleotide polymorphisms (SNPs) data using the populational Thousand Genomes Project dataset. Our results highlight the model’s ability to generalize to diverse populations in the CARTaGENE and Montreal Heart Institute biobanks and that predictions remain robust to high levels of missing SNPs. We show that, despite the lack of North African populations in the training dataset, the model learns latent representations that reflect meaningful population structure for North African individuals in the biobanks. To improve model transparency, we apply Saliency Maps, DeepLift, GradientShap and Integrated Gradients attribution techniques and evaluate their performance in identifying SNPs leveraged by the model. Using DeepLift, we show that model’s predictions are driven by population-specific signals consistent with those identified by traditional population genetics metrics. This work presents a generalizable and interpretable deep learning framework for genetic ancestry inference in large-scale biobanks with genetic data. By enabling more widespread genomic ancestry characterization in these cohorts, this study contributes practical tools for integrating genetic data into downstream biomedical applications, supporting more inclusive and equitable healthcare solutions.
- Open Access
Predictive Gene Discovery with EPCY: A Density-Based Alternative to DE analysis
Identifying predictive genes from high-throughput data remains a key challenge in biomedical research. Most current approaches rely on statistical tests to select differentially expressed genes (DEGs), which may not align with the goal of predicting outcomes. We present EPCY, a method that ranks genes based on their predictive power using cross-validated classifiers and density estimation, without relying on null hypothesis testing. Applied to both bulk and single-cell RNA sequencing datasets, EPCY consistently outperforms benchmark DEG-based methods in selecting robust candidate genes. It also demonstrates greater stability across varying cohort sizes, enabling reproducible gene prioritization even in large, heterogeneous datasets. EPCY provides interpretable predictive scores, facilitating candidate selection aligned with downstream validation goals.
Open AccessPredictive Gene Discovery with EPCY: A Density-Based Alternative to DE analysis
Identifying predictive genes from high-throughput data remains a key challenge in biomedical research. Most current approaches rely on statistical tests to select differentially expressed genes (DEGs), which may not align with the goal of predicting outcomes. We present EPCY, a method that ranks genes based on their predictive power using cross-validated classifiers and density estimation, without relying on null hypothesis testing. Applied to both bulk and single-cell RNA sequencing datasets, EPCY consistently outperforms benchmark DEG-based methods in selecting robust candidate genes. It also demonstrates greater stability across varying cohort sizes, enabling reproducible gene prioritization even in large, heterogeneous datasets. EPCY provides interpretable predictive scores, facilitating candidate selection aligned with downstream validation goals.
- Open Access
- 22 May 2025
- Published by Springer Nature in Nature Cancer
- Vol. 6 (8) , 1419-1437
Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer
Melanoma and non-small cell lung cancer (NSCLC) display exceptionally high mutational burdens. Hence, immune targeting in these cancers has primarily focused on tumor antigens (TAs) predicted to derive from nonsynonymous mutations. Using comprehensive proteogenomic analyses, we identified 589 TAs in cutaneous melanoma (n = 505) and NSCLC (n = 90). Of these, only 1% were derived from mutated sequences, which was explained by a low RNA expression of most nonsynonymous mutations and their localization outside genomic regions proficient for major histocompatibility complex (MHC) class I-associated peptide generation. By contrast, 99% of TAs originated from unmutated genomic sequences specific to cancer (aberrantly expressed tumor-specific antigens (aeTSAs), n = 220), overexpressed in cancer (tumor-associated antigens (TAAs), n = 165) or specific to the cell lineage of origin (lineage-specific antigens (LSAs), n = 198). Expression of aeTSAs was epigenetically regulated, and most were encoded by noncanonical genomic sequences. aeTSAs were shared among tumor samples, were immunogenic and could contribute to the response to immune checkpoint blockade observed in previous studies, supporting their immune targeting across cancers.
- 22 May 2025
- Published by Springer Nature in Nature Cancer
- Vol. 6 (8) , 1419-1437
Open AccessTumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer
Melanoma and non-small cell lung cancer (NSCLC) display exceptionally high mutational burdens. Hence, immune targeting in these cancers has primarily focused on tumor antigens (TAs) predicted to derive from nonsynonymous mutations. Using comprehensive proteogenomic analyses, we identified 589 TAs in cutaneous melanoma (n = 505) and NSCLC (n = 90). Of these, only 1% were derived from mutated sequences, which was explained by a low RNA expression of most nonsynonymous mutations and their localization outside genomic regions proficient for major histocompatibility complex (MHC) class I-associated peptide generation. By contrast, 99% of TAs originated from unmutated genomic sequences specific to cancer (aberrantly expressed tumor-specific antigens (aeTSAs), n = 220), overexpressed in cancer (tumor-associated antigens (TAAs), n = 165) or specific to the cell lineage of origin (lineage-specific antigens (LSAs), n = 198). Expression of aeTSAs was epigenetically regulated, and most were encoded by noncanonical genomic sequences. aeTSAs were shared among tumor samples, were immunogenic and could contribute to the response to immune checkpoint blockade observed in previous studies, supporting their immune targeting across cancers.
- Open Access
- 19 May 2025
- Published by Elsevier in Blood Neoplasia
- Vol. 2 (3) , 100118
Replication of a GWAS signal near HLA-DQA2 with AML using a disease-only cohort and external population-based controls
- 19 May 2025
- Published by Elsevier in Blood Neoplasia
- Vol. 2 (3) , 100118
Open AccessReplication of a GWAS signal near HLA-DQA2 with AML using a disease-only cohort and external population-based controls